Prof Trevor J Powles, MBBS, PhD, FRCP is an expert in Oncology at Barts Health NHS Trust (United Kingdom). As of November 2026, ScienceLeadR ranks Trevor J Powles in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Trevor J Powles has authored 334 publications, the most recent in 2022, and is an investigator in 1 clinical trial. SLR score: 1,186 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Trevor J Powles, MBBS, PhD, FRCP Barts Health NHS Trust United Kingdom
1 186 ScienceLeadR Reputation 1186
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1985 - 2022
Source: PubMed

National Health Service

1995 - 2022

Barts Health NHS Trust

2022 - 2022

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 334

Citations

Citations: 37 048 1st author: 63 Last author: 61 Unique author: 36


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
PMID 35065204 — testicular neoplasms, diagnosis, therapeutics, seminoma
Ann Oncol Top journal2022141
Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.
PMID 28654362 — breast neoplasms, neoplasms, breast, medical oncology, diphosphonates
J Clin Oncol20173
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
PMID 29242041 — mortality, breast neoplasms, neoplasms, drug therapy, chemotherapy, adjuvant, breast, therapeutics, chemotherapy
Lancet Oncol Top journal20171,095
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
PMID 29117498 — breast neoplasms, neoplasms, breast, therapeutics
N Engl J Med Top journal20171,714
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
PMID 27400912 — breast neoplasms, case-control studies, neoplasms, odds ratio, breast, polymorphism, single nucleotide, tamoxifen
Breast Cancer Res Treat20167

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map